Finally, to determine whether adding PEGeg-IFN-α2b and GM-CSF to high-dose imatinib may further improve the cytogenetic and molecular response rates in CML patients, 94 patients were treated with imatinib 800 mg/day for the first 6 months and then randomized to continue high-dose imatinib alone or in combination with PEGeg-IFN-α2b at the dosage of 0.5 μg/kg per week and GM-CSF 125 mg/m2 three times weekly [61]. This evidence concerns the gene CSF2 and chronic myelogenous leukemia, BCR-ABL1 positive.